{"entity":{"id":"mirasol","kind":"trial","name":"MIRASOL / GOG-3045","aka":[],"tldr":"The first ADC to extend life in ovarian cancer, for the roughly one-third of tumours with high folate receptor alpha.","summary":"MIRASOL, also GOG-3045, trial NCT04209855 sponsored by ImmunoGen, now AbbVie, and published in the New England Journal of Medicine in 2023, produced the first antibody-drug conjugate to extend life in ovarian cancer, for the roughly one-third of platinum-resistant tumours with high folate receptor alpha expression. It randomised 453 women with one to three prior lines to mirvetuximab soravtansine or chemotherapy, met its primary progression-free survival endpoint and improved overall survival, leading to full approval in March 2024; ocular toxicity is frequent but reversible with eye-drop prophylaxis. OnCo links it to ovarian cancer, antibody-drug conjugates, folate receptor alpha, mirvetuximab soravtansine, Kathleen N. Moore, Ursula A. Matulonis and the GOG Foundation. Whether the drug can move into platinum-sensitive or maintenance settings is the open question.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT04209855","url":"https://clinicaltrials.gov/study/NCT04209855"},{"label":"NEJM 2023","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2309169"}],"tags":[],"related":[],"cancers":["ovarian","platinum-resistant-ovarian-cancer"],"sections":[],"technologies":["adc"],"targets":["folr1"],"drugs":["mirvetuximab-soravtansine"],"companies":["gog-foundation"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["kathleen-moore","ursula-matulonis"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04209855","phase":"3","setting":"Platinum-resistant ovarian cancer with high folate receptor alpha expression, 1-3 prior lines: mirvetuximab soravtansine vs chemotherapy","sponsor":"ImmunoGen (AbbVie)","result":"OS 16.46 vs 12.75 months (HR 0.67).","started":"2019-12-31","startedType":"actual","yearReported":2023,"enrolled":453,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival","primary":true,"unit":"months","arms":[{"name":"Mirvetuximab","n":227,"value":5.62},{"name":"Chemotherapy","n":226,"value":3.98}],"hr":0.65,"ci":[0.52,0.81],"source":"https://www.nejm.org/doi/full/10.1056/NEJMoa2309169"},{"endpoint":"Overall survival","unit":"months","arms":[{"name":"Mirvetuximab","value":16.46},{"name":"Chemotherapy","value":12.75}],"hr":0.67,"ci":[0.5,0.89],"source":"https://www.nejm.org/doi/full/10.1056/NEJMoa2309169"}]},"route":"/trials/mirasol/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/"}],"drug":[{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/"}],"company":[{"id":"gog-foundation","kind":"company","name":"GOG Foundation","route":"/companies/gog-foundation/"}],"person":[{"id":"kathleen-moore","kind":"person","name":"Kathleen N. Moore","route":"/people/kathleen-moore/"},{"id":"ursula-matulonis","kind":"person","name":"Ursula A. Matulonis","route":"/people/ursula-matulonis/"}],"paper":[{"id":"paper-mirasol-nejm-2023","kind":"paper","name":"MIRASOL: mirvetuximab soravtansine versus chemotherapy in folate receptor alpha-high platinum-resistant ovarian cancer","route":"/key-papers/paper-mirasol-nejm-2023/"}]}}